Skip to main content
Fig. 3 | BMC Gastroenterology

Fig. 3

From: Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study

Fig. 3

The proportion of symptoms-free days and nights after 1, 2, 4 weeks of treatment (per protocol set). A, the proportion of heartburn-free days after 1, 2, 4 weeks of treatment. B, the proportion of acid regurgitation-free days after 1, 2, 4 weeks of treatment. C, the proportion of heartburn-free nights after 1, 2, 4 weeks of treatment. D, The proportion of acid regurgitation-free nights after 1, 2, 4 weeks of treatment

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us